STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026
MWN-AI** Summary
STAAR Surgical Company (NASDAQ: STAA), recognized as a global leader in phakic intraocular lenses (IOLs), will host an earnings conference call and webcast on March 3, 2026, to discuss its financial results for the fourth quarter and fiscal year ended January 2, 2026. The results will be released after market close on the same day, followed by the call scheduled for 5:30 p.m. ET (2:30 p.m. PT).
The earnings call will cover a range of topics, including an overview of the company’s operations and financial performance in fiscal year 2025. Notable points of discussion will include the recovery of operations in China, efforts towards inventory normalization, and maintaining cost discipline. Additionally, updates will be provided on the company’s ongoing manufacturing expansion in Switzerland, as well as advancements in its innovation pipeline. Furthermore, the management will outline strategic focuses for 2026.
Investors and interested parties can access the live webcast via the link provided in the announcement or through the "Investors" section of the STAAR website. A replay of the webcast will be made available for 90 days following the event.
STAAR Surgical specializes in developing and manufacturing Implantable Collamer® Lenses (ICLs), which offer vision correction solutions without the need for glasses or contact lenses. The company has sold over 3.5 million ICLs across more than 75 countries. With its headquarters in Lake Forest, California, STAAR operates facilities focused on research, development, and manufacturing in both California and Switzerland.
Potential investors are encouraged to keep an eye on the company’s disclosures, as STAAR intends to use its website to communicate important non-public information in compliance with regulatory obligations.
MWN-AI** Analysis
As STAAR Surgical (NASDAQ: STAA) prepares for its fourth quarter and fiscal year 2025 earnings release on March 3, 2026, attention will focus on key aspects of its financial and operational performance. Investors should tune in to the earning calls scheduled for 5:30 p.m. ET, where management intends to cover pivotal topics including a review of operational improvements, inventory normalization, and a strategic focus for 2026.
The report will provide insights into STAAR's recovery in China, a critical market for the company's phakic IOLs, particularly with its EVO ICL™ line. Market analysts anticipate updates on manufacturing expansion efforts in Switzerland, which could enhance production capacity amidst rising demand for advanced vision correction solutions. Given STAAR's historical focus on cost discipline, any commentary on maintaining or improving operational efficiency will be closely scrutinized.
Investors should also be attentive to the company's innovation pipeline, as developments here could significantly impact sales projections and competitive positioning. The management's assessment of financial results will likely hinge on how effectively STAAR navigates ongoing global economic uncertainties, aspects of international trade, and procurement challenges, particularly regarding supply chains and raw materials.
Given the company's established history and market leadership in Implantable Collamer lenses, the fourth quarter results could provide a cue for long-term investor sentiment. If results show consistent revenue growth and solid operational management, especially in recovering key markets like China, it may drive stock appreciation.
Nevertheless, potential investors should consider inherent risks, such as regulatory uncertainties and market adoption rates of new products. Close monitoring of the earnings call and subsequent market reactions will be critical for stakeholders looking to make informed decisions regarding STAAR's performance moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress.
Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast
Date: Tuesday, March 3, 2026
Time: 5:30 p.m. ET/ 2:30 p.m. PT
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd
Topics on the call will include:
- Review of Fiscal Year 2025 Operations and Financial Results
- China Recovery and Operational Improvements
- Inventory Normalization
- Cost Discipline
- Update on Manufacturing Expansion in Switzerland
- Innovation Pipeline Progress
- 2026 Strategic Focus
The live webcast, including an option to pre-register, can be accessed at the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/ . A webcast replay will be available at the same link for at least 90 days.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3.5 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com . To learn more about STAAR, visit www.staar.com .
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2026 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to expected or future financial performance. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at https://investors.staar.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260223189943/en/
Investor/Media Contact: ir@staar.com
Connie Johnson
cjohnson@staar.com
(626) 303-7902 (ext. 2207)
Asia Investor/Media Contact:
Niko Liu, CFA
nliu@staar.com
United States: (626) 303-7902 (ext. 3023)
Hong Kong: +852 6092-5076
FAQ**
How does STAAR Surgical Company STAA plan to address the challenges posed by global economic conditions in its upcoming financial results for fiscal year 2025?
Can STAAR Surgical Company STAA provide insights into the expected impact of the China recovery on its sales and operations?
What specific innovations are being prioritized in STAAR Surgical Company STAA's 2026 strategic focus, as mentioned in the upcoming earnings call?
How is STAAR Surgical Company STAA managing inventory normalization and cost discipline in light of recent operational improvements?
**MWN-AI FAQ is based on asking OpenAI questions about STAAR Surgical Company (NASDAQ: STAA).
NASDAQ: STAA
STAA Trading
1.09% G/L:
$17.59 Last:
347,408 Volume:
$17.11 Open:
